


# Enable Midstream Partners Annual Plan Review

## 2019 Key Points

This contract is scheduled for renewal on 01/01/2021.


### Average Members Per Month



### 2019 Total Net Plan Cost




### Utilizers 2018 vs. 2019



**4% increase in utilizers**  
**4,097 utilizers in 2019, up 158 from 2018**


### Net PMPM



**Net PMPM increased by 8.0% YoY to \$75.89 (Rebates with a \$29.37 reduction)**

**ESI Peer Group PMPM \$106.72 (4.8% trend)**

### Rx Fills 2018 vs. 2019



**Increase in utilizers drove 1.0% increase in total Rx count in 2019**

Non-Specialty			
	2018	2019	ESI Peer Group
Net PMPM	\$40.94	\$40.49	\$59.88
Net PMPM Trend	--	-1.1%	(2.1%)
Utilizers	3936	4093	--
Utilizer Trend	--	4.0%	--
Net Plan Cost	\$2,231,298	\$2,287,775	--
Net Plan Cost Trend	--	2.5%	--

Specialty			
	2018	2019	ESI Peer Group
Net PMPM	\$29.34	\$35.41	\$46.84
Net PMPM Trend	--	20.7%	15.1%
Utilizers	63	70	--
Utilizer Trend	--	11.1%	--
Net Plan Cost	\$1,599,345	\$2,000,861	--
Net Plan Cost Trend	--	25.1%	--

## Top Indications by Plan Cost Net

2019

2018

% Change

Top Indications by Plan Cost Net															
2019											2018				% Change
Management Strategy	Rank	Peer Rank	Indication	Adjusted Rxs	Patients	Plan Cost Net	Generic Fill Rate	Peer Generic Fill Rate	Plan Cost Net PMPM	Rank	Adjusted Rxs	Patients	Generic Fill Rate	Plan Cost Net PMPM	Plan Cost Net PMPM
ST/PA/DQM	1	1	INFLAMMATORY CONDITIONS	523	59	\$947,572	46.8%	49.6%	\$16.77	1	388	50	50.3%	\$11.63	44.2%
ST/PA/DQM	2	3	DIABETES	4,436	242	\$454,365	41.3%	44.8%	\$8.04	2	3,999	242	45.1%	\$6.85	17.4%
PA	3	23	ENZYME DEFICIENCIES	13	1	\$313,709	0.0%	1.0%	\$5.55	4	15	1	0.0%	\$4.19	32.6%
ST/PA/DQM	4	5	MULTIPLE SCLEROSIS	43	4	\$233,881	30.2%	24.1%	\$4.14	3	45	4	20.0%	\$4.63	-10.5%
PA/DQM	5	2	CANCER	256	44	\$183,347	93.8%	85.1%	\$3.24	6	224	33	92.4%	\$3.25	-0.3%
ST/PA/DQM	6	6	PAIN/INFLAMMATION	5,551	1,195	\$174,972	96.1%	96.2%	\$3.10	5	5,574	1,210	95.2%	\$3.62	-14.5%
ST/DQM	7	12	CONTRACEPTIVES	3,174	370	\$151,344	81.4%	85.3%	\$2.68	8	3,041	362	86.0%	\$2.40	11.7%
ST/PA/DQM	8	8	ASTHMA	2,842	587	\$149,034	61.4%	46.0%	\$2.64	7	2,787	600	57.6%	\$2.94	-10.3%
ST/DQM	9	10	HIGH BLOOD PRESS/HEART DISEASE	13,014	1,006	\$129,427	96.6%	98.3%	\$2.29	10	11,643	930	96.8%	\$2.06	11.3%
ST/PA	10	11	ATTENTION DISORDERS	1,383	201	\$118,330	83.7%	52.1%	\$2.09	9	1,333	199	52.7%	\$2.29	-8.4%
			Total Top 10:	31,235		\$2,855,983	81.0%		\$50.54		29,049		81.6%	\$43.85	15.3%
			Differences Between Periods:	2,186		\$466,222	-0.6%		\$6.70						

## Key Insights

- Inflammatory Conditions experienced the largest percent change in PMPM
  - Up 44.2% or \$5.14 increase in Net PMPM
  - Increase in Humira and Enbrel utilization
- Significant reduction in cancer Rx, but Tasigna therapy was initiated and kept the net PMOM flat

**Top Drugs by Plan Cost Net**
**2019      2018      % Change**

Management Strategy	Rank	Peer Rank	Brand Name	Indication	Adj. Rxs	Pts.	Plan Cost Net	Plan Cost Net PMPM	Rank	Adj. Rxs	Pts.	Plan Cost Net PMPM	Plan Cost Net PMPM
PA	1	185	RAMICTI*	ENZYME DEFICIENCIES	13	1	\$313,709	\$5.55	1	15	1	\$4.19	32.6%
ST/PA/DQM	2	1	HUMIRA PEN*	INFLAMMATORY CONDITIONS	72	7	\$275,662	\$4.88	2	49	12	\$3.39	43.8%
ST/PA	3	2	HUMIRA(CF) PEN*	INFLAMMATORY CONDITIONS	49	7	\$197,187	\$3.49	138	2	2	\$0.11	3060.4%
PA/DQM	4	84	TASIGNA*	CANCER	9	1	\$126,342	\$2.24					
PA/DQM	5	7	TRULICITY	DIABETES	253	27	\$100,163	\$1.77	9	169	24	\$1.28	38.0%
ST/PA/DQM	6	100	AVONEX*	MULTIPLE SCLEROSIS	15	1	\$94,189	\$1.67	6	12	1	\$1.39	19.6%
ST/PA/DQM	7	17	COPAXONE*	MULTIPLE SCLEROSIS	15	2	\$83,981	\$1.49	3	24	2	\$2.54	-41.4%
ST/PA	8	4	ENBREL SURECLICK*	INFLAMMATORY CONDITIONS	16	3	\$72,526	\$1.28	42	3	1	\$0.37	250.6%
N/A	9	1547	HEMOFIL M*	HEMOPHILIA	4	1	\$69,575	\$1.23	11	3	1	\$1.14	8.3%
ST/PA/DQM	10	197	NUCALA*	ASTHMA	24	2	\$62,678	\$1.11	10	25	2	\$1.20	-7.6%

**Key Insights**

- 17 of the Top 25 are Specialty Drugs
  - Making up 80.6% of Top 25 Spend
- Inflammatory Conditions is the main indication driving cost

**Clinical Insights**

Metrics	01/19-12/19	01/18-12/18
Total Savings (plan cost)	\$883,365	\$1,164,888
Prior Authorization - Savings (plan cost)	\$286,448	\$512,401
Step Therapy - Savings (plan cost)	\$406,113	\$443,520
Total Appeals	19	8
Appeal Approvals	12	4
Appeal Denials	7	4
Coverage Review Approval Rate	80.87%	83.78%


## Confidio RED List

2019 Total Potential Savings - \$79,494		
	Tier 1	Tier 2
Savings	\$12,671	\$66,823
Members Impact	18	998
Primary Targeted Medications	Duexis and Vimovo	PPIs and Nasal Sprays

## SaveOn SP

Specialty Program with an estimated Plan Savings of \$353k

**SAVEONSP**  
**Enable Midstream**

<b>CLIENT SUMMARY</b>	<b>BENEFIT FOR PATIENTS AND THE CLIENT</b> 
<p><b>4.8 K</b> total lives</p> <p><b>53</b> members benefiting</p> <p><b>440</b> impacted claims</p> <p><b>\$274</b> average member copay per rx</p>	<p><b>\$353 K</b> annual plan savings *</p> <p><b>\$6.20</b> PMPM client savings*</p> <p><b>\$0</b> remaining member cost</p>

Every month you lose \$29,454 without SaveonSP setup

\*Net of program shared savings fee. Savings based on sponsor's utilization, the most restrictive state benchmark and ESI National Preferred, Basic and High Performance Formulary. Savings may vary based on sponsor's actual utilization or a different benchmark or formulary. Savings do not represent any type of guarantee by SaveonSP or ESI.

## Rebates

3Q17	4Q17	1Q18	2Q18	3Q18	4Q18	1Q19	2Q19	3Q19	Total
\$653,520.61	\$78,202.69	\$259,756.25	\$277,165.12	\$279,307.19	\$279,307.49	\$524,693.67	\$348,405.48	\$443,104.29	\$3,143,462.79

**PMF Remaining: \$31,332.00**

**➤ Confidio Contact:**

**Rick Hilliges** | Account Executive  
[rick.hilliges@confidio.com](mailto:rick.hilliges@confidio.com)  
 P: (402) 517-8816